Genexine is a growing global biotechnology company, and operates on the management principle of “TIPS”
Genexine in involved in the research and development (R&D) of innovative immunotherapeutic drugs and next-generation antibody fusion proteins. The company is also actively involved in commercializing these products. In addition, Genexine is currently developing innovative therapeutic drugs to fulfill its mission of saving patient lives and improving their quality of life.
Saving the lives of patients by developing innovative biologics.
To realize our grand dream of saving patient lives, we are earnest and passionate in all our endeavors. We also strongly believe in the culture of working together, and promoting corporate growth and development, as well as individual and career growth.
We value making an effort to yield the best outcomes through passion and engagement, based on our diligence toward achieving organizational and personal goals.
We uphold the attitude of improving outcomes and reinvigorating the organization by creating a synergistic environment. We cooperate closely by sharing beneficial ideas and information within the organization and believe in teamwork based on mutual respect and consideration.
We believe in having a positive attitude toward performance, making an effort to proactively present alternatives to solve a problem. With positive thinking, this is achievable without feeling frustrated or giving up when facing the challenging task of developing a novel drug that does not exist anywhere in the world.
Our vision is to become a leader in the global biotechnology market by 2030, through the development of innovative novel drugs.
Innovative novel drugs are difficult to make. The R&D process involves many trials and errors, and presents several challenges. To combat these challenges, Genexine aims to create an environment where every member of the company enjoys developing novel drugs and finds meaning in the experience, fostering both self-growth and ensuring employees enjoy working together toward a common goal.
GX-188E has entered clinical trial stage 2
of early Phase2 for cervical cancer patients.
Held groundbreaking ceremony
for the Magok R&D Center
Signed a contract
for clinical development of HyLeukin-7
& Immunogate Inhibitor Combination
Therapy with Roche and NIT
Clinically approved 1b / 2a
in Korea for combined use of immune
checkpoint inhibitors in patients
with triple negative breast cancer
Genexine is dedicated toward the R&D of novel drugs, based on its own proprietary technology. The company employs key research personnel with decades of knowledge and understanding in the development of novel drugs.
Genexine aims to achieve the challenging mission of “developing innovative novel drugs that give patients with intractable diseases a new life” and to make the leap forward to becoming a world-class biotechnology company. The company is fully committed to developing novel drugs with a passion and vision to successfully complete the mission, no matter what it takes.
After graduating from Yonsei University with a degree in biochemistry, Dr. Sung received his PhD degree in molecular biology from the University of Minnesota in the United States and worked as a researcher at the Department of Pathology at Harvard Medical School. In July 1989, he began his professorship at the Department of Life Science in Pohang University of Science and Technology and continued in this position. In June 1999, he founded Genexine and subsequently grew the company to a worth of over 1 trillion won. To develop novel drugs with “Open Innovation” and “Together Culture” as the foundations for success, we motivated professionals to develop novel drugs using Genexine’s outstanding proprietary technologies, joint development efforts with a fusion of technologies from major domestic and foreign pharmaceutical companies, and establishment of joint ventures in different parts of the world.
President Dr. Jung Won Woo leads the Protein Manufacturing Technology Research Institute, Business and Clinical Development. She is working in charge of all clinical development and global license deals. Dr. Woo received her BS and MS degrees in pharmacy from Seoul National University and her PhD degree in microbiology from Cornell University. After completing her post-doc fellowship at Harvard Medical School, she started working as a senior researcher at Samsung Bio Research Institute and researcher at Convergent Research Consortium for Immunologic Disease (CRCID) in Seoul St. Mary’s Hospital. She works closely with various internal and external affiliates to support Genexine’s vision of becoming an innovative biotechnology company through the development of first-in-the-world novel drugs. Based on her extensive experience, she is also involved in developing the strategic direction of the company from a long-term perspective of global partnerships, commercialization, and clinical applications.
Vice President You Suk Suh leads the DNA Manufacturing Technology Institute. Dr. Suh joined Genexine in 2006 and held multiple leadership positions over the years in Genexine, including Head of Bio Efficacy Center before taking his current position. Also, Dr. Suh has been served as Head of DNA vaccine research institute and head QA. Dr. Suh received his Ph.D. degree from POSTECH (Korea) and postdoctoral training at German Primate Center (DPZ)(Germany). He conducted gene therapy vaccine research at Alexander-von-Humboldt foundation in Germany and HIV DNA vaccine research at POSTECH prior to joining Genexine.
After his retirement from Catholic Medical Center, Dr. Jong Sup Park joined Genexine in March 2019 to serve as the company’s chief medical officer (CMO). Dr. Park had previously served as a practicing physician in the gynecology department at Seoul St. Mary’s Hospital and as a research professor at Johns Hopkins Medical School. Dr. Park has been a respected gynecologic oncologist and is recognized as a renowned biomedical researcher of HPV and cervical cancer in South Korea for the past three decades. He also established the Asia-Oceania Research Organization on Genital Infection and Neoplasia (AOGIN) to educate clinicians and health workers living in the Asia-Pacific region. Based on his wealth of experience, Dr. Park oversees the clinical progress of a therapeutic DNA vaccine for cervical cancer at Genexine.
Sung June Hong, as Vice President and CFO, is in charge of financial, legal, patent, and investor communication(IR) matters to establish advanced management systems, and play the role of a business partner to the businesses. He has earned his bachelor's and master's degrees in business administration from Yonsei University and also received master's degree in laws from Vanderbilt Law School. As a financial and legal expert qualified in South Korea and the United States, he has been managing strategic, legal, and financial aspects of various enterprises for 28 years. Based on a variety of experiences and knowledge from various companies including Arthur Andersen, Philip Morris, Nike, Schneider Electric, and recently as CFO at Handok and COO/CFO at ROKIT Healthcare, he will be instrumental to the growth of Genexine as a global innovative company leading the pharmaceutical and biotechnology industry.
Kyu Don Kim joined Genexine in December 2015 as Excutive Vice President and he is in charge of Business. Prior to joining Genexine, Dr Kim was CEO at CKD and Bio Business Teamof New Business Division in Samsung Electronics and held the position of Vice President. Prior to that, he served as Head of Product Development Division in LG Life Sciences Ltd. Dr Kim received his B.S in Biochemistry from Yonsei University, MBA degree fromSogang University and Ph.D. in Chemistry from Universityof Northern Illinois and postdoctoral training at University of Florida, Gainesville.